Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells
Open Access
- 1 June 1999
- journal article
- Published by Wiley in European Journal of Immunology
- Vol. 29 (6) , 1850-1857
- https://doi.org/10.1002/(sici)1521-4141(199906)29:06<1850::aid-immu1850>3.0.co;2-n
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Altered Peptide Ligand–Induced Partial T Cell Activation: Molecular Mechanisms and Role in T Cell BiologyAnnual Review of Immunology, 1996
- Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic proteinNature, 1996
- Low avidity recognition of self-antigen by T cells permits escape from central toleranceImmunity, 1995
- An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitisImmunity, 1995
- Antigen Analogs/MHC Complexes as Specific T Cell Receptor AntagonistsAnnual Review of Immunology, 1994
- T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitisEuropean Journal of Immunology, 1994
- An autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel route for escape from tolerance inductionInternational Immunology, 1993
- Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunityCell, 1993
- Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptorCell, 1992
- T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitisNature, 1986